The drug candidate is designed as a one-time treatment to “inactivate the PCSK9 gene in the liver to durably lower blood LDL-C,” Verve said in a news release. The phase 1 trial recruited 10 patients with familial hypercholesterolemia, a genetic abnormality. Participants were either given sub-therapeutic doses, such as 0.1 or 0.3 milligrams per kilogram, or potentially therapeutic doses, including 0.45 or 0.6 milligrams per kilogram.
Among the patients treated with possible therapeutic doses, LDL cholesterol was reduced between 39% and 55%. Eli Lilly plans to help with future studies of the experimental treatment after the drugmaker invested $310 million to sponsor the research and acquire rights, according to The New York Times.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.